Drilldown: Medicines
Appearance
Medicines > onset
:
Motor improvement over days at therapeutic dose
or
Prostate volume reduction over 6-12 months 
:
Motor improvement over days at therapeutic dose
or
Prostate volume reduction over 6-12 months 
Use the filters below to narrow your results.
[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor (dual type I/II)]] (1) ·
[[:Category:Androgen_modulators|Androgen modulator]] (1) ·
[[:Category:Antiparkinsonians|Antiparkinsonian]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) ·
[[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] (2)
0.5 mg PO once daily (1) ·
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) ·
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1)
'''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.

